Sor­ry No­vo: Sanofi wins Abl­ynx over with $4.8B buy­out bid, bag­ging nanobody plat­form tech

Sanofi $SNY has struck again — this time ac­quir­ing Abl­ynx, the Bel­gian biotech that has turned down two pre­vi­ous bids by No­vo Nordisk, for $4.8 bil­lion.

The French drug­mak­er agreed to pay a whop­ping $55.81 per share to swal­low Abl­ynx’s an­ti­body tech­nol­o­gy, al­most 50% high­er than No­vo’s $33.60 per share of­fer. In­vestors clear­ly liked how Abl­ynx held out, send­ing its shares $ABLX up 17% in pre­mar­ket trad­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN